In Vivo Targeting of Tumor Endothelial Cells by Systemic Delivery of Lentiviral Vectors
- 10 August 2003
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 14 (12) , 1193-1206
Abstract
Tumor angiogenesis is a rate-limiting factor for tumor growth, and the endothelial cells of tumor vessels display specific features that can be exploited for the selective delivery of cancer therapeutics. To specifically target exogenous genes to angiogenic tumor vessels, we generated a panel of vesicular stomatitis virus-pseudotyped lentiviral vectors (LVs) engineered for endothelial cell (EC)-specific expression. We cloned a wide repertoire of transcription regulatory sequences from genes preferentially expressed in ECs (Tie1, Tie2, Flk-1, VE-Cad, and ICAM-2) into self-inactivating LVs to drive expression of the marker gene encoding green fluorescent protein (GFP) or of the conditionally toxic gene encoding nitroreductase, and compared them with the ubiquitously expressing phosphoglycerate kinase (PGK) and cytomegalovirus (CMV) promoters. We evaluated the efficiency and specificity of vector expression in vitro in a panel of human primary cultures, including ECs, fibroblasts, neurons, lymphocytes, and hematopoietic progenitors, and in tumor cell lines. We found that vectors containing promoter and enhancer sequences from the Tie2 gene achieved remarkable specificity of expression in ECs in vitro and in vivo. On intravenous delivery into tumor-bearing mice, the Tie2 vector targeted expression to the ECs of tumor vessels. In contrast, LVs carrying the PGK or CMV promoter gave widespread GFP marking in ECs and non-ECs of tumors and other organs. The previously reported upregulation of the Tie2 gene in ECs activated for angiogenesis may explain the remarkable selectivity of expression of the Tie2 vector in ECs of tumor vessels. The new vector provides the means for selective delivery of gene therapy to tumor sites in vivo.Keywords
This publication has 41 references indexed in Scilit:
- Specific transgene expression in human and mouse CD4+cells using lentiviral vectors with regulatory sequences from theCD4 geneBlood, 2003
- A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryosThe FASEB Journal, 2002
- Molecular Evidence of Lentiviral Vector-Mediated Gene Transfer into Human Self-Renewing, Multi-potent, Long-Term NOD/SCID Repopulating Hematopoietic CellsMolecular Therapy, 2002
- Tumor Regression by Targeted Gene Delivery to the NeovasculatureScience, 2002
- Transcriptional Targeting of Lentiviral Vectors by Long Terminal Repeat Enhancer ReplacementJournal of Virology, 2002
- Efficient Gene Delivery and Targeted Expression to Hepatocytes In Vivo by Improved Lentiviral VectorsHuman Gene Therapy, 2002
- Tissue-specific gene therapy directed to tumor angiogenesisGene Therapy, 2001
- Calcineurin Controls the Transcription of Na+/Ca2+ Exchanger Isoforms in Developing Cerebellar NeuronsJournal of Biological Chemistry, 2000
- The Human ICAM-2 Promoter is Endothelial Cell-specific in Vitro and in Vivo and Contains Critical Sp1 and GATA Binding SitesJournal of Biological Chemistry, 1998
- The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable MetaboliteHuman Gene Therapy, 1997